H.D. Smith names new VP generic pharmaceuticals
SPRINGFIELD TOWNSHIP, Ill. — Wholesaler H.D. Smith last week promoted Dmitrey Kuznetsov to VP generic pharmaceuticals.
In this new role, Kuznetsov will be responsible for the generic pharmaceutical category to improve profits by driving a consistent and comprehensive strategy. Adding to his current responsibilities with generic sourcing, he will assume responsibility for the commercialization of generics. This will allow Kuznetsov to continue to deliver incremental value and still lead H. D. Smith’s generic sourcing activities. In his expanded role, Kuznetsov will help develop programs and pricing initiatives that will optimize generics for H. D. Smith’s customers.
Kuznetsov joined H. D. Smith in 2012 as VP generic pharmaceuticals sourcing, and was responsible for the development, implementation and management of the generic pharmaceuticals sourcing strategy. He led the team in establishing strategic relationships with trading partners that have resulted in H. D. Smith’s competitive generics portfolio. In addition, his team was able to negotiate improved terms and conditions with trading partners that have allowed H. D. Smith to be contemporary with contracts.
NPA brings back Adam Finney as SVP member services
WASHINGTON — The Natural Products Association on Monday announced the hire of Adam Finney as SVP member services.
Finney previously served as VP member services with NPA for 10 years before leaving to pursue a position as VP membership and communications at the Food Processing Suppliers Association, where he has worked for the last four years. In his new role, Finney will be directly involved in developing and implementing strategies to grow NPA’s membership base.
“Considering Adam’s proven track record of superior member services, his extensive knowledge and expertise of associations, and his familiarity with NPA’s dynamic membership base and industry issues, there is no one better suited for this position,” said Daniel Fabricant, NPA executive director and CEO. “His addition will ensure our members are being served with the highest level of excellence, while also further solidifying our commitment to expanding our membership in both the near and long term. Additionally, Adam is returning to the association at a time of exciting new initiatives, such as our recently announced partnership with Southeast NPA on the 2014 SOHO EXPO. His involvement in these efforts will prove invaluable over the coming months and he’ll play a key role in making them successful.”
“I’m thrilled for the opportunity to rejoin NPA and to work alongside Dr. Fabricant,” Finney said. “Dr. Fabricant has done a tremendous job over the past several months to increase NPA’s visibility, provide more value to members, and ultimately ensure that the association’s membership continues to grow. Since taking over the helm of NPA, Dr. Fabricant has welcomed more than 127 new members to the association, and I’m looking forward to doing my part to guarantee the successes of the past several months continue long into the future," he said. "NPA is growing because Americans want more natural products and our member companies are delivering for them. This is a powerful trend toward natural that will only get stronger as our industry’s products continue to provide healthy and balanced results for millions of families.”
Finney also has served as membership director at the California Credit Union League and director of membership and chapter relations at the California Restaurant Association. He is a graduate of California State University, Long Beach, where he received his Bachelor of Science degree in business administration.
J&J acquires Alios BioPharma for $1.8 billion
NEW BRUNSWICK, N.J. — Johnson & Johnson on Tuesday announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.8 billion in cash. The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.
"We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy," said William Hait, global head, research and development, Janssen Pharmaceutical Companies of Johnson & Johnson. "AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five."
The closing is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the fourth quarter of 2014.
"Alios BioPharma's pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation," added Johan Van Hoof, global head, infectious diseases and vaccines, Janssen. "This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide."
Loading Post Please Wait...